Please login to the form below

Not currently logged in
Email:
Password:

Meda denies takeover report

Swedish pharmaceutical company Meda has denied a media report that Valeant has made a takeover approach for it

Sweden-based Meda has denied reports that Canada-based Valeant Pharmaceuticals International has made a takeover bid for the company.

In a statement Meda said: "Meda's board of directors has not received an approach of the kind that is described in the article. However, there are several collaborations between Meda and Valeant including joint ventures in Canada, Mexico and Australia."

A deal for Meda could be valued at more than $4bn, the Wall Street Journal reported on Tuesday.

Earlier in 2011 Valeant dropped a $5.7bn approach for Cephalon after Israel's Teva Pharmaceutical agreed to buy the US-based pharmaceutical firm for $81.50 a share, beating Valeant's $73-a-share bid.

When contacted by PMLiVE, Valeant said it declined to comment on market speculation.

Valeant recently agreed to acquire Janssen Pharmaceuticals' Ortho Dermatologics and Sanofi's Dermik.

27th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics